StockData
INSMED Inc logo

INSMED Inc (INSM) stock

INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/3099% above fair value
$121.86−1.02 (-0.83%)

Close on Nov 17, 2026Market cap $26.73BP/E –Yield –

Insmed operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Insmed's operating cash flow for the twelve months ending Sep 30, 2026 was -$595.62M. For fiscal 2025 it was -$935.01M. The highest annual figure on record is -$7.72M in fiscal 2010.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$935.01M–
FY2024Dec 31, 2024-$683.88M–
FY2023Dec 31, 2023-$536.25M–
FY2022Dec 31, 2022-$400.44M–
FY2021Dec 31, 2021-$363.30M–
FY2020Dec 31, 2020-$219.35M–
FY2019Dec 31, 2019-$250.65M–
FY2018Dec 31, 2018-$257.98M–
FY2017Dec 31, 2017-$159.62M–
FY2016Dec 31, 2016-$146.71M–
FY2015Dec 31, 2015-$100.70M–
FY2014Dec 31, 2014-$64.42M–
FY2013Dec 31, 2013-$46.66M–
FY2012Dec 31, 2012-$31.01M–
FY2011Dec 31, 2011-$30.21M–
FY2010Dec 31, 2010-$7.72M–
FY2009Dec 31, 2009-$11.01M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$36.46M–
Q2 FY2026Jun 30, 2026-$88.83M–
Q1 FY2026Mar 31, 2026-$222.74M–
Q4 FY2025Dec 31, 2025-$247.60M–
Q3 FY2025Sep 30, 2025-$219.76M–
Q2 FY2025Jun 30, 2025-$205.57M–
Q1 FY2025Mar 31, 2025-$262.09M–
Q4 FY2024Dec 31, 2024-$195.98M–
Q3 FY2024Sep 30, 2024-$180.92M–
Q2 FY2024Jun 30, 2024-$122.95M–
Q1 FY2024Mar 31, 2024-$184.04M–
Q4 FY2023Dec 31, 2023-$130.82M–
Q3 FY2023Sep 30, 2023-$136.33M–
Q2 FY2023Jun 30, 2023-$122.79M–
Q1 FY2023Mar 31, 2023-$146.30M–
Q4 FY2022Dec 31, 2022-$103.15M–
Q3 FY2022Sep 30, 2022-$89.83M–
Q2 FY2022Jun 30, 2022-$102.30M–
Q1 FY2022Mar 31, 2022-$105.16M–
Q4 FY2021Dec 31, 2021-$84.13M–
Q3 FY2021Sep 30, 2021-$75.45M–
Q2 FY2021Jun 30, 2021-$75.44M–
Q1 FY2021Mar 31, 2021-$128.28M–
Q4 FY2020Dec 31, 2020-$66.79M–
Q3 FY2020Sep 30, 2020-$58.67M–
Q2 FY2020Jun 30, 2020-$35.95M–
Q1 FY2020Mar 31, 2020-$57.94M–
Q4 FY2019Dec 31, 2019-$44.40M–
Q3 FY2019Sep 30, 2019-$52.37M–
Q2 FY2019Jun 30, 2019-$80.03M–
Q1 FY2019Mar 31, 2019-$73.85M–
Q4 FY2018Dec 31, 2018-$70.16M–
Q3 FY2018Sep 30, 2018-$65.49M–
Q2 FY2018Jun 30, 2018-$54.91M–
Q1 FY2018Mar 31, 2018-$67.41M–
Q4 FY2017Dec 31, 2017-$48.22M–
Q3 FY2017Sep 30, 2017-$38.24M–
Q2 FY2017Jun 30, 2017-$36.25M–
Q1 FY2017Mar 31, 2017-$36.91M–
Q4 FY2016Dec 31, 2016-$57.96M–

More Insmed figures

See a number that looks wrong?